Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation: The ARC-High Bleeding Risk Trade-off Model.

JAMA cardiology·2021
Same author

Does the left circumflex coronary artery location impact on the success of chronic total occlusion recanalization? A single-center cohort study.

Scandinavian cardiovascular journal : SCJ·2020
Same author

Suitability for elderly with heart disease of a QR code-based feedback of drug intake: Overcoming limitations of current medication adherence telemonitoring systems.

International journal of cardiology·2020
Same author

When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y<sub>12</sub> Inhibition Induced by Ticagrelor.

Journal of the American Heart Association·2020
Same author

Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.

European heart journal·2020
Same author

Early Adverse Impact of Transfusion After Transcatheter Aortic Valve Replacement: A Propensity-Matched Comparison From the TRITAVI Registry.

Circulation. Cardiovascular interventions·2020
Same journal

Aortic Valve Replacement in Women of Reproductive Age.

Journal of the American College of Cardiology·2026
Same journal

Sudden Death in Cardio-Kidney-Metabolic Patients: Insights From FINE-HEART.

Journal of the American College of Cardiology·2026
Same journal

Ultra-Thin Sirolimus-Eluting Versus Everolimus-Eluting Stents in Diabetic Multivessel Coronary Artery Disease Patients: The TUXEDO-2 Trial.

Journal of the American College of Cardiology·2026
Same journal

Reframing Cardiometabolic Risk and Frailty Through Sarcopenic Obesity.

Journal of the American College of Cardiology·2026
Same journal

Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology.

Journal of the American College of Cardiology·2026
Same journal

The Measure of a Leader: Lessons in Leadership From Eugene Braunwald.

Journal of the American College of Cardiology·2026
See all related articles

Related Experiment Videos

Antithrombotic therapy in the elderly.

Davide Capodanno1, Dominick J Angiolillo

  • 1University of Florida College of Medicine-Jacksonville, Jacksonville, Florida 32209, USA.

Journal of the American College of Cardiology
|November 13, 2010
PubMed
Summary
This summary is machine-generated.

Elderly patients with atherothrombotic disease require careful antithrombotic therapy. Understanding age-related risks and drug interactions is crucial for preventing recurrent ischemic events in this growing population.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Background:

  • Antithrombotic therapy is vital for preventing recurrent ischemic events in atherothrombotic disease.
  • Elderly patients are more susceptible to adverse effects of antithrombotic drugs due to pharmacokinetic and pharmacodynamic changes.
  • Polypharmacy in the elderly exacerbates the risk of adverse drug interactions with antithrombotic agents.

Purpose of the Study:

  • To provide an overview of current evidence on antithrombotic therapy in elderly patients.
  • To focus on the management of antithrombotic treatment in elderly patients with coronary artery disease.

Main Methods:

  • Review of current available evidence.
  • Focus on treatment strategies for coronary artery disease in the elderly.

Main Results:

  • Established benefits of antithrombotic pharmacotherapy in the elderly.
  • Increased vulnerability of elderly individuals to adverse antithrombotic drug effects.
  • Significant role of drug-drug interactions due to polypharmacy in enhancing adverse event risks.

Conclusions:

  • Antithrombotic management in the elderly requires careful consideration of age-specific factors.
  • Strategies must address increased vulnerability and polypharmacy to optimize outcomes in elderly patients with atherothrombotic disease.
  • Further research and tailored approaches are essential for safe and effective antithrombotic therapy in the aging population.